title: Chronotherapy of ovarian cancer: effect on blood variables and serum cytokines. A case report.
abstract: A 7-year-old patient with Stage III-c ovarian cancer was subjected to 8 cycles, approximately four weeks apart, of chronobiologically-optimized treatments with combination of three anti-cancer agents: Four cycles at AM, Cytoxan and PM, cis-Platinum; four cycles at AM, Adriamycin and PM, cis-Platinum. A second look laporoscopy revealed clean intestines, no definite masses in the pelvis area although there was an apparent mass in the right upper pelvis and several slightly enlarged lymph nodes in the base of mesentery. Six cycles of Taxol were administered at about Noon. Seven months remission appeared evident as judged by no changes in monthly examinations, in blood work or in CA-125 marker levels which remained below 12 U/ml. During the eight month the CA-125 marker began to rise, 36 then to 52 U/ml. A second 6 cycle series of Taxol was initiated but the CA-125 marker continued to rise, 57, 65, 72, 86, and 87 U/ml level. The patient declined in spirit, in well-being and expired 2 weeks later, 31 months after the initial diagnosis of cancer. Blood hematology, chemistry, and cytokines variables were analyzed at about weekly intervals. Significant reductions in total WBC, neutrophiles and platelet levels were evident during the second week of all cycle treatments, while increases were noted in serum levels of IL-2, IL-6 and IL-10 following Cytoxan-cis-Platinum-Adriamycin, but not Taxol. After each infusion moderate and temporary increases in RBC levels were noted. The treatments impact on hematology, chemistry, cytokine variables and on the integrity of the patient, are presented and briefly discussed.
authors.affiliation: Edward Hines, Jr., VA Medical Center Hines, IL 60141, USA. kanabrocki@aol.com
authors.forename: E L
authors.initials: EL
authors.lastname: Kanabrocki
authors.forename: R C
authors.initials: RC
authors.lastname: Hermida
authors.forename: M
authors.initials: M
authors.lastname: Torossov
authors.forename: M B
authors.initials: MB
authors.lastname: Haseman
authors.forename: K
authors.initials: K
authors.lastname: Bettis
authors.forename: R M I
authors.initials: RM
authors.lastname: Young
authors.forename: J P
authors.initials: JP
authors.lastname: Mathew
authors.forename: R
authors.initials: R
authors.lastname: Potkul
authors.forename: W J M
authors.initials: WJ
authors.lastname: Hrushesky
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019454:Chronotherapy; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines